PDS Biotechnology Corporation
Last updated September 27, 2026
Organization details
- Legal name
- PDS Biotechnology Corporation
- Former names
- Edge Therapeutics, Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Princeton
- Headquarters state / province
- New Jersey
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- PDSB
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001472091
- EIN
- 26-4231384
Board of directors
-
Arnold James Banaag · DirectorSince 2026
-
Frank Bedu-Addo · Director · President/CEOSince 2023
-
Gregory Gene Freitag · DirectorSince 2023
-
Ilian Iliev · DirectorSince 2023
-
Kamil Ali-Jackson · DirectorSince 2023
-
Otis W. Brawley · DirectorSince 2023
-
Patrick Soon-Shiong · DirectorSince 2026
-
Richard Sykes · DirectorSince 2023
-
Stephen C. Glover · DirectorSince 2023
Chief executives
Frank Bedu-Addo
· President/CEO
Dates unknown
Director election results
Annual meeting of August 10, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
73.3%
-
76.7%
Board connections
5 of this board's directors also sit on 7 other boards.
- via Otis W. Brawley
- via Gregory Gene Freitag
- via Patrick Soon-Shiong
- via Otis W. Brawley
- via Otis W. Brawley
- via Stephen C. Glover
- via Kamil Ali-Jackson
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 28, 2025 | Gregory Gene Freitag Director | Open-market purchase | +15,060 | $1.66 | $25,000 |
| Feb 28, 2025 | Stephen C. Glover Director | Open-market purchase | +15,061 | $1.66 | $25,001 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.